It is now well established that women who carry mutations in the PALB2 gene are at similar breast cancer risks as those who carry mutations in BRCA2 [6, 7]) making many rethink the appropriateness of the initial “moderate or intermediate risk gene” label [8]. This evidence concerns the gene BRCA2 and breast cancer.